Zobrazeno 1 - 10
of 35
pro vyhledávání: '"M. Sarosdy"'
Autor:
D Albert, M Sarosdy, D Lamb, Michael Clayton, Roohollah Sharifi, Paul Siami, M. Lee, Michael D. Strub
Publikováno v:
Scopus-Elsevier
The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ce5cc8c9753a403bbfa14c2b7b7d997
https://doi.org/10.1097/00001813-199104000-00005
https://doi.org/10.1097/00001813-199104000-00005
Autor:
T, Saric, Z, Brkanac, D A, Troyer, S S, Padalecki, M, Sarosdy, K, Williams, L, Abadesco, R J, Leach, P, O'Connell
Publikováno v:
International journal of cancer. 81(2)
Genetic alterations in primary prostate cancer (CaP) have been extensively studied, yet little is known about the genetic mechanisms underlying progression of primary CaP to metastatic prostate cancer. As a result, it is not possible to distinguish c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f2b4030a452ba3deecdaf7678cb5c0e8
https://pubmed.ncbi.nlm.nih.gov/10188722
https://pubmed.ncbi.nlm.nih.gov/10188722
Autor:
P, Schellhammer, R, Sharifi, N, Block, M, Soloway, P, Venner, A L, Patterson, M, Sarosdy, N, Vogelzang, J, Jones, G, Kolvenbag
Publikováno v:
Urology. 47(1A)
To review the outcome of therapy with maximal androgen blockade and compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing hormone analogue (LHRH-A) therapy, in patients with untreat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ec1ee28313455726012b2a71e864a79f
https://pubmed.ncbi.nlm.nih.gov/8560679
https://pubmed.ncbi.nlm.nih.gov/8560679
Autor:
P, Schellhammer, R, Sharifi, N, Block, M, Soloway, P, Venner, A L, Patterson, M, Sarosdy, N, Vogelzang, J, Jones, G, Kolvenbag
Publikováno v:
Urology. 45(5)
To compare the efficacy and safety of bicalutamide and flutamide, each used in combination with luteinizing hormone-releasing analogue (LHRH-A) therapy, in patients with untreated metastatic (Stage D2) prostate cancer.Randomized, double-blind (for an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44f32c5f6196b4ee2bdee857092d28ba
https://pubmed.ncbi.nlm.nih.gov/10096411
https://pubmed.ncbi.nlm.nih.gov/10096411
Autor:
M, Sarosdy
Publikováno v:
Anti-cancer drugs. 3
Eighty-seven patients with carcinoma in situ of the bladder were randomized to receive either 10 MU (low dose, 38 patients) or 100 MU (high dose, 47 patients) of recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::74c6381cfef7bb68c2ecfa900e5dd0ae
https://pubmed.ncbi.nlm.nih.gov/1611111
https://pubmed.ncbi.nlm.nih.gov/1611111
Publikováno v:
Cancer Chemotherapy and Pharmacology. 8
Hormone manipulation has been standard therapy for metastatic adenocarcinoma of the prostate for many years. Recently cytotoxic drugs have been studied, but their effectiveness has been limited, indicating the need for new therapeutic approaches. Bas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b14241c229680e15d5b1355653d20e7
https://doi.org/10.1007/bf00254047
https://doi.org/10.1007/bf00254047
Autor:
D A, Swanson, W A, Anthony, O L, Avant, W P, Curtis, J M, Ferrell, G T, Keegan, T R, McMillin, P C, Peters, M, Sarosdy, M M, Warren
Publikováno v:
Texas medicine. 83(9 Pt 2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c01bed8112c324e639d237fd2c353f95
https://pubmed.ncbi.nlm.nih.gov/3672402
https://pubmed.ncbi.nlm.nih.gov/3672402
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.